{"id":"W3165727183","doi":"10.1016/s1470-2045(21)00290-4","title":"Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Oncology; Context (archaeology); Internal medicine; Clinical endpoint; Refractory (planetary science); Population; Lymphoma; Hodgkin lymphoma; Randomized controlled trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002795498,0.0007421004,0.001545653,0.0008178973,0.003233362,0.003877271,0.001626739,0.06224779,0.006589104],"category_scores_gemma":[0.01685266,0.0007943775,0.001086559,0.0006671164,0.002665657,0.002745498,0.001810334,0.03890005,0.004573219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00398348,"about_ca_system_score_gemma":0.003102163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004037821,"about_ca_topic_score_gemma":0.006319252,"domain_scores_codex":[0.9976454,0.0007739581,0.0002637359,0.0002999489,0.0005823091,0.0004346097],"domain_scores_gemma":[0.9926363,0.004661692,0.0005017587,0.0001845175,0.0009167235,0.001099057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006379623,0.00001382832,0.0002872177,0.00004904586,0.00002042824,0.0008436879,0.00008076152,0.00003795529,0.0001047912,0.001471025,0.9930069,0.004020508],"study_design_scores_gemma":[0.0002613649,0.00007068826,0.001132159,0.000367972,0.00006903338,0.001563976,0.0003165129,0.0002590111,0.000189457,0.006046934,0.9896673,0.000055658],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0002152223,0.002020784,0.00003062065,0.9656528,0.03048501,0.000006366412,0.00004052749,0.000009012635,0.001539711],"genre_scores_gemma":[0.002535572,0.001009603,0.00005981731,0.9486998,0.0429784,0.00002157814,0.00002753689,0.00001270035,0.004655015],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.06224779,"threshold_uncertainty_score":0.02890235,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1022012804690907,"score_gpt":0.3670396438270521,"score_spread":0.2648383633579615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}